Detected ·
TriGemX Bio
$94M—
TriGemX Bio (formerly Kallyope) closed a $94M financing co-led by TCG, TCGX and Viking Global Investors to advance elismetrep, a potential first-in-class oral treatment for acute migraine, into Phase 3 trials.
- Website
- www.kallyope.com
- linkedin.com/company/kallyope
- Amount
- $94 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-10-02 16:09:31 UTC
- Signal ID
- 6f69e454-27e1-4fb2-8b76-45bf6ca6de86
As the API returns it
{
"id": "6f69e454-27e1-4fb2-8b76-45bf6ca6de86",
"created_at": "2026-10-02T16:09:31.909863Z",
"company_name": "TriGemX Bio",
"company_website_url": "www.kallyope.com",
"company_linkedin_url": "https://www.linkedin.com/company/kallyope",
"event_type": "funding",
"funding_amount": 94000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*TriGemX Bio (formerly Kallyope) closed a $94M financing co-led by TCG, TCGX and Viking Global Investors to advance elismetrep, a potential first-in-class oral treatment for acute migraine, into Phase 3 trials.*"
}